Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer

Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and efficacy of AMR with primary prophylactic pegfilgra...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2023-12-01
Serija:	Thoracic Cancer
Teme:	amrubicin febrile neutropenia pegfilgrastim second‐line chemotherapy small cell lung cancer
Online dostop:	https://doi.org/10.1111/1759-7714.15140
Oznake:	Označite Brez oznak, prvi označite!